LIVER DIGEST

A weekly update of PLRC happenings

September 24, 2020



www.livercenter.pitt.edu

Please acknowledge support from the PLRC (NIH/NIDDK P30DK120531) in your publications and presentations.

In this issue

- Faculty Highlight
- Seminar/Meetings Announcements
- Special Funding Opportunities
- Funding Opportunities

FACULTY HIGHLIGHT

Dr. Samira Kiani published an article in Nature Cell Biology, titled "Synthetic immunomodulation with a CRISPR super-repressor in vivo." The manuscript gained media attention, including in the Pittwire News outlet. You can read the full article by clicking here.

NEXT VIRTUAL SEMINAR: TUESDAY, SEPTEMBER 29th AT 12:00 PM

Our next virtual seminar is scheduled for **Tuesday, September 29** at **12:00 PM.** A Zoom link to access the seminar has been sent out to all members via email. **Dr. Henry Dong**, PLRC member, will be

giving a presentation on his research and the title of the talk will be: "FoxO1 in Insulin Resistance and Diabetic Dyslipidemia."

If you have any questions, please email Amanda Bytzura at bytzuraam@upmc.edu.

FINAL SOTA LECTURE SEPTEMBER 29 AT 7:00 AM

The Division of Gastroenterology, Hepatology and Nutrition will be hosting their final State-of-the-Art Lecture of the series **on Tuesday**, **September 29 at 7:00 am**. Dr. Adam Slivka will present, "Evaluation & Management of Nonvariceal UGI & LGI Bleeding."

Please click here for the Microsoft Teams link to join the meeting.

You can also join by dialing 412-447-5295 and entering the Conference ID: 992 093 294#

COMMUNITY LIVER ALLIANCE

VIRTUAL LIVER CANCER CONFERENCE

SATURDAY, SEPTEMBER 26, 2020 | 8:00 AM - 2:30 PM REGISTRATION IS FREE

Concurrent Educational Sessions:

Health Care Providers (CME) and Patients/Caregivers Roundtable (Non-CME)

8:00 a.m. Welcome and Overview

Dulabh K Monga, MD and Satdarshan (Paul) Monga, MD Course Directors Suzanna Masartis Executive Director, Community Liver Alliance

8:10 a.m. Keynote 1: The State of Art in Pathogenesis and Diagnosis

Augusto Villanueva, MD, PhD Liver Cancer Program - Tisch Cancer Institute Divisions of Liver Diseases/ Hematology and Medical Oncology - Department of Medicine Icahn School of Medicine at Mount Sinai

9:00 a.m. Risk Factors for HCC and HCC Surveilance

Jaideep Beharl, MD, PhD Transplant Hepatology UPMC Center for Liver Diseases

9:30 a.m. Role of Surgical Resection and Transplantation in HCC Management

David Geller, MD Director, UPMC Liver Cancer Center

10:00 a.m. Concurrent Session Role of Locoregional Therapies in HCC Management

Andrew Klobuka, MD Department of Radiology, Allegheny Health Network

Patient Roundtable Discussion

Brittany Morocco, MPAS, PA-C Senior Physician Assistant **UPMC Liver Cancer Center**

10:30 a.m. Medical Management of HCC

Dulabh K Monga, MD Program Director Hematology Oncology Fellowship Assistant Professor of Medicine Allegheny Health Network









11:00 a.m. In Search of New Therapeutic Targets

Satdarshan (Paul) Monga, MD Director, Pittsburgh Liver Research Center UPMC Endowed Chair for Experimental Patholog University of Pittsburgh, School of Medicine

11:30 a.m. Radiation Therapy for HCC

Alexander Kirichenko, MD System Director, SRS/SRT Programs Allegheny Health Network

12:00-12:30 p.m. Lunch Break

12:30-1:00 p.m. Sponsor Exhibit Visits

1:00-1:50 p.m. Keynote 2: State of the Art in Intrahepatic Cholangiocarcinoma: Diagnosis and Treatment

Mitesh Borad MD Associate Professor of Medicine Consultant, Div. of Hematology/Oncology, Department of Intern Medicine Consultant, Department of Molecular Medicine Mayo Clinic

2:00-2:45 p.m. Case Presentations

Moderators: Dr. Mitesh Borad and Dr. Dulabh Mc Resectable/Transplantable HCC Akshata Moghe, MD, PhD Advanced Fellow/Transplant Hepatology UPMC Starzl Transplant Services

Non-Resectable Non-Transplantable HCC and Medical and Locoregional Options

Srividya Srinivasamaharaj, MD Hematology Oncology Fellow Allegheny Health Network

Intrahepatic Cholangiocarcinoma

Srividua Srinivasamaharaj, MD Hematology Oncology Fellow Allegheny Health Network

2:45-3:00 p.m. Case Presentation Q&A

FOR MORE INFORMATION AND TO REGISTER, VISIT COMMUNITYLIVERALLIANCE.ORG/LIVER-CANCER-CONFEREN

SPECIAL FUNDING OPPORTUNITY

The University of Pittsburgh is expanding its successful partnership with Takeda Pharmaceutical Co. and is seeking requests for proposals for funded research projects across a range of categories. Funding can be up to NIH (R01) levels and most projects are expected to be in the range of 18-30 months.

Available categories are as follows:

Liver Disease

- Advanced/late stage liver disease (F3, F4 NASH only), antifibrosis drivers
- Hepatocyte rejuvenation, regeneration, replacement
- · Primary sclerosing cholangitis
- Rare disease and genetic linked: Wilson's

Translational and Clinical

 Clinically meaningful targets, biomarkers, models, assays, endpoints

- Causal validation of targets, therapeutic modulation that recapitulates human biology
- Patient progression and disease outcome predictions
- Patient identification and stratification strategies

Areas of no interest include

- Metabolic NASH/NAFLD
- Hepatitis

Criterial for Project selection

- Transformative approach, platform, or biology
- Clearly defined proposal with a testable hypothesis
 - Specify activities to be performed in investigator lab vs those by Takeda team
 - Insight and/or expertise in the disease biology
- Availability of in vitro and in vivo models to robustly test the therapeutic hypothesis

Dr. Alex Goddard will be presenting Takeda's areas of interest on Sept 25th from 3-4pm via Zoom. Please register **here**

Short, non-confidential proposals are due October 15th and will be

reviewed by the Innovation Institute prior to submission. The application can be found at the <u>linked site</u>.

If you have any questions, please contact Amanda Bytzura at bytzuraam@upmc.edu.

FUNDING OPPORTUNITIES

Liver Scholar Award

American Liver Foundation (ALF)

ALF Postdoctoral Research Fellowship Award

American Liver Foundation (ALF)

BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)

(RFA-MH-20-556)

National Institute of Mental Health

National Center for Complementary and Integrative Health

National Eye Institute

National Institute on Aging

National Institute on Alcohol Abuse and Alcoholism

National Institute of Biomedical Imaging and Bioengineering

Eunice Kennedy Shriver National Institute of Child Health and

Human Development

National Institute on Drug Abuse

National Institute on Deafness and Other Communication Disorders
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): February 11, 2021; October 19, 2021,
by 5:00 PM local time of applicant organization.

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

(RFA-NS-21-010)

National Institute of Neurological Disorders and Stroke

National Center for Complementary and Integrative Health

National Eye Institute

National Institute on Alcohol Abuse and Alcoholism

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Eunice Kennedy Shriver National Institute of Child Health and

Human Development

National Institute on Drug Abuse

National Institute of Dental and Craniofacial Research

National Institute of Diabetes and Digestive and Kidney Diseases

Office of Research on Women's Health

Application Receipt Date(s): November 18, 2020, March 24, 2021,

July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022, by 5:00PM local time of applicant organization. Alltypes of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.



Copyright © 2019 Pittsburgh Liver Research Center, All rights reserved.

Our mailing address is:

Pittsburgh Liver Research Center 200 Lothrop St. | Pittsburgh, PA 15261